Gene · 7517
Papers2,149
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 2,149
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Construction of a DNA damage repair gene signature for predicting prognosis and immune response in breast cancer. | Front Oncol | 2022 | 36713553 | PubTator, text mining | PubMed |
| Gene polymorphisms and risk of head and neck squamous cell carcinoma: a systematic review. | Rep Pract Oncol Radiother | 2022 | 36632298 | PubTator, text mining | PubMed |
| Gene polymorphisms and prognosis of head and neck squamous cell carcinoma: a systematic review. | Rep Pract Oncol Radiother | 2022 | 36632296 | PubTator, text mining | PubMed |
| Genomics and Epigenomics in the Molecular Biology of Melanoma-A Prerequisite for Biomarkers Studies. | Int J Mol Sci | 2022 | 36614156 | PubTator, text mining | PubMed |
| Targeting the DNA Damage Response Machinery for Lung Cancer Treatment. | Pharmaceuticals (Basel) | 2022 | 36558926 | PubTator, text mining | PubMed |
| High-Risk Human Papillomavirus Infection in Lung Cancer: Mechanisms and Perspectives. | Biology (Basel) | 2022 | 36552201 | PubTator, text mining | PubMed |
| The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review. | Cancers (Basel) | 2022 | 36551737 | PubTator, text mining | PubMed |
| Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations. | BMC Cancer | 2022 | 36544182 | PubTator, text mining | PubMed |
| DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities. | Int J Mol Sci | 2022 | 36499000 | PubTator, text mining | PubMed |
| Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality. | Cancers (Basel) | 2022 | 36497275 | PubTator, text mining | PubMed |
| Association of polymorphisms in TGFB1, XRCC1, XRCC3 genes and CD8 T-lymphocyte apoptosis with adverse effect of radiotherapy for prostate cancer. | Sci Rep | 2022 | 36494413 | PubTator, text mining | PubMed |
| Systematic proximal mapping of the classical RAD51 paralogs unravel functionally and clinically relevant interactors for genome stability. | PLoS Genet | 2022 | 36374936 | PubTator, text mining | PubMed |
| Classic and New Markers in Diagnostics and Classification of Breast Cancer. | Cancers (Basel) | 2022 | 36358862 | PubTator, text mining | PubMed |
| The Role of Single Nucleotide Polymorphisms in Transporter Proteins and the Folate Metabolism Pathway in Delayed Methotrexate Excretion: A Case Report and Literature Review. | Pharmgenomics Pers Med | 2022 | 36349164 | PubTator, text mining | PubMed |
| Sister chromatid exchanges induced by perturbed replication can form independently of BRCA1, BRCA2 and RAD51. | Nat Commun | 2022 | 36344511 | PubTator, text mining | PubMed |
| Targeting DNA damage response as a potential therapeutic strategy for head and neck squamous cell carcinoma. | Front Oncol | 2022 | 36338767 | PubTator, text mining | PubMed |
| Non-coding RNAs and glioma: Focus on cancer stem cells. | Mol Ther Oncolytics | 2022 | 36321132 | PubTator, text mining | PubMed |
| Altered transcription factor targeting is associated with differential peripheral blood mononuclear cell proportions in sarcoidosis. | Front Immunol | 2022 | 36311769 | PubTator, text mining | PubMed |
| Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer. | Cell Death Dis | 2022 | 36307400 | PubTator, text mining | PubMed |
| Triple kill: DDR inhibitors, radiotherapy and immunotherapy leave cancer cells with no escape. | Acta Biochim Biophys Sin (Shanghai) | 2022 | 36305726 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7517/papers?page=10